Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
InfuSystem directly provides infusion pumps and related medical device equipment, plus lifecycle management services.
|
$177.09M |
$8.63
-3.79%
|
|
PERF
Perfect Corp.
HD skin diagnostics deployed in aesthetic clinics, representing healthcare-oriented diagnostic software.
|
$176.20M |
$1.72
+0.58%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$176.00M |
$1.85
-2.12%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$175.85M |
$1.86
+13.41%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$174.24M |
$2.23
+9.02%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$169.72M |
$6.21
+1.22%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$169.06M |
$4.83
+2.11%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$165.48M |
$0.27
|
|
MXCT
MaxCyte, Inc.
ExPERT medical device platform for cell engineering and its related consumables constitute MaxCyte's core product offerings in healthcare hardware.
|
$164.17M |
$1.55
+0.65%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$161.58M |
$58.70
+5.42%
|
|
ACU
Acme United Corporation
SmartCompliance RFID First Aid kits indicate the company produces medical devices & biometrics-enabled safety products.
|
$161.13M |
$42.63
+0.79%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$159.99M |
$2.80
+0.72%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$158.47M |
$18.64
-2.20%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$155.01M |
$0.68
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$154.10M |
$3.23
+1.10%
|
|
QIPT
Quipt Home Medical Corp.
Quipt designs/markets medical devices and biometric sensing technology used in home respiratory care and diabetes monitoring (CGMs).
|
$153.36M |
$3.54
+0.14%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$153.31M |
$4.28
+0.71%
|
|
RELL
Richardson Electronics, Ltd.
Medical devices and equipment manufacturing including CT X-ray tubes and related products remain part of the portfolio.
|
$153.05M |
$10.57
+2.52%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$152.31M |
$2.15
-2.05%
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$151.95M |
$16.18
-1.34%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$149.90M |
$10.57
-3.65%
|
|
APYX
Apyx Medical Corporation
APYX designs and sells medical devices (Renuvion helium plasma platform and AYON body contouring system) used in surgical procedures.
|
$149.01M |
$4.00
-0.62%
|
|
PRLD
Prelude Therapeutics Incorporated
Prelude is a clinical-stage biotech focused on oncology, with an advanced pipeline targeting SMARCA2/SMARCA4 and related cancer pathways.
|
$148.86M |
$2.65
-3.80%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$148.83M |
$4.01
-3.02%
|
|
RCMT
RCM Technologies, Inc.
RCMT's offerings align with Healthcare Services & Facilities through its healthcare staffing/model and service delivery to care institutions.
|
$148.80M |
$20.14
+0.20%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$148.44M |
$2.08
-1.18%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$148.04M |
$1.65
-2.08%
|
|
IPHA
Innate Pharma S.A.
Innate Pharma focuses on oncology therapies, including antibody-based approaches, making Biotech - Oncology a core business area.
|
$147.54M |
$1.80
+3.45%
|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$145.13M |
$29.10
+0.07%
|
|
CNTX
Context Therapeutics Inc.
CNTX is a biotech company focused on oncology therapeutics (solid tumors) leveraging immunotherapy approaches.
|
$144.42M |
$1.55
-3.13%
|
Showing page 23 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
